Edwards Lifesciences Corporation (EW)

New York Stock Exchange:
EW
| Latest update: Oct 15, 2025, 6:34 PM

Stock events for Edwards Lifesciences Corp. (EW)

Over the past six months, Edwards Lifesciences' stock price has been influenced by several events, including a 17.26% increase between October 3, 2024, and October 2, 2025. In Q2 2025, Edwards Lifesciences reported strong results, with sales growing 11.9% to $1.53 billion and adjusted EPS at $0.67, leading to raised full-year guidance. Analyst ratings and price targets were adjusted by Stifel, Wells Fargo & Company, Barclays, Canaccord Genuity Group, JPMorgan Chase & Co., Evercore ISI, BTIG Research, and William Blair. Edwards Lifesciences announced a $500 million accelerated share repurchase program. The TAVR market experienced a slowdown, leading EW to revise its TAVR outlook for 2024 to +5-7% year-over-year growth.

Demand Seasonality affecting Edwards Lifesciences Corp.’s stock price

Explicit information regarding the demand seasonality for Edwards Lifesciences Corp.'s products and services is not readily available. The nature of medical device demand, particularly for critical cardiovascular conditions, may suggest less pronounced seasonality compared to consumer goods.

Overview of Edwards Lifesciences Corp.’s business

Edwards Lifesciences Corporation is a global medical technology company specializing in innovative solutions for advanced cardiovascular diseases, operating within the Health Technology sector, specifically in the Medical Specialties and Medical Instruments Manufacturing industries. The company is headquartered in Irvine, California, and its primary focus is on structural heart disease and critical care monitoring. Major products and technologies include Transcatheter Aortic Valve Replacement (TAVR) with the Edwards SAPIEN family of valves, Transcatheter Mitral and Tricuspid Therapies (TMTT) focusing on heart valve repair and replacement technologies, Surgical Structural Heart including surgical valve repair and replacement devices, and Critical Care, which was acquired by BD in 2024.

EW’s Geographic footprint

Edwards Lifesciences has a significant global presence with its global headquarters in Irvine, California. The company maintains manufacturing facilities in Draper, Utah; Costa Rica; the Dominican Republic; Puerto Rico; Singapore; and Limerick, Ireland. Edwards Lifesciences markets its products through a direct sales force and a network of independent distributors across North America, Europe, and Asia-Pacific. Geographically, the company generates revenue from the United States, Europe, Japan, and the Rest of World.

EW Corporate Image Assessment

There is no specific information detailing events that have negatively impacted Edwards Lifesciences Corp.'s brand reputation in the past year. The company is recognized for its patient-focused medical innovations and its strong performance, product innovation, and market leadership in structural heart technologies.

Ownership

Edwards Lifesciences is primarily owned by institutional shareholders, who hold approximately 85.49% of the company's stock, while retail investors own about 13.29%, and Edwards Lifesciences insiders hold 1.22%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., JPMorgan Chase & Co, State Street Corp, and Wellington Management Group Llp. The largest individual shareholder is Michael A. Mussallem, who owns 4.45 million shares, representing 0.76% of the company.

Price Chart

$73.36

3.54%
(1 month)

Top Shareholders

The Vanguard Group, Inc.
11.88%
BlackRock, Inc.
9.43%
JPMorgan Chase & Co.
4.54%
State Street Corp.
4.35%
Wellington Management Group LLP
3.36%
The Bank of New York Mellon Corp.
2.98%
Geode Holdings Trust
2.16%
GFH HFEVA LLC
2.13%
Prudential Financial, Inc.
2.06%
DZ BANK AG Deutsche Zentral-Genossenschaftsbank
1.55%
Government of Norway
1.31%
Morgan Stanley
1.27%
Ninety One Plc
1.26%
Brown Advisory Management LLC
1.24%
MLM Trust B
1.19%
MW Group LP
1.17%
Northern Trust Corp.
1.04%
Deutsche Bank AG
1.02%
The Wellcome Trust Ltd.
0.81%
Holocene Advisors, LP
0.80%

Trade Ideas for EW

Today

Sentiment for EW

News
Social

Buzz Talk for EW

Today

Social Media

FAQ

What is the current stock price of Edwards Lifesciences Corp.?

As of the latest update, Edwards Lifesciences Corp.'s stock is trading at $73.36 per share.

What’s happening with Edwards Lifesciences Corp. stock today?

Today, Edwards Lifesciences Corp. stock is down by -3.54%, possibly due to news.

What is the market sentiment around Edwards Lifesciences Corp. stock?

Current sentiment around Edwards Lifesciences Corp. stock is negative, based on recent news, trading volume, and analyst opinions.

Is Edwards Lifesciences Corp.'s stock price growing?

Over the past month, Edwards Lifesciences Corp.'s stock price has decreased by -3.54%.

How can I buy Edwards Lifesciences Corp. stock?

You can buy Edwards Lifesciences Corp. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol EW

Who are the major shareholders of Edwards Lifesciences Corp. stock?

Major shareholders of Edwards Lifesciences Corp. include institutions such as The Vanguard Group, Inc. (11.88%), BlackRock, Inc. (9.43%), JPMorgan Chase & Co. (4.54%) ... , according to the latest filings.